In Vitro and In Vivo Neutralizing Efficacy of Monoclonal Antibodies Against Sars-Cov-2 Variants in Kidney Transplant Recipients

Overview of attention for article published in Transplant International, July 2024

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (55th percentile)

Mentioned by

twitter: 4 X users

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 2,441 followers.

RT @atranscendedman: Study shows sotrovimab can still neutralize some new COVID-19 variants in kidney transplant patients but less effectiv…

01 Aug 2024

Reply Repost Favourite

RT @atranscendedman: Study shows sotrovimab can still neutralize some new COVID-19 variants in kidney transplant patients but less effectiv…

31 Jul 2024

Reply Repost Favourite

RT @atranscendedman: Study shows sotrovimab can still neutralize some new COVID-19 variants in kidney transplant patients but less effectiv…

31 Jul 2024

Reply Repost Favourite

Study shows sotrovimab can still neutralize some new COVID-19 variants in kidney transplant patients but less effectively than against the original strain. Higher doses or combinations of monoclonal antibodies may be needed for better protection. https:

31 Jul 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.